Pulmonary
Partner With Us
Advertisement
Conexiant chevron_right Pulmonary chevron_right Cost-Effectiveness of Shortened Antibiotic Treatment for VAP
From the Journals

Cost-Effectiveness of Shortened Antibiotic Treatment for VAP

Researchers conducted a planned economic analysis of the phase IV REGARD-VAP trial, which assessed a short-course antibiotic treatment strategy for ventilator-associated pneumonia.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Individualized short-course antibiotic treatment strategy for ventilator-associated pneumonia is likely cost-effective.
  2. The approach was noninferior to standard care for the 60-day composite endpoint of death or pneumonia recurrence.
  3. Researchers conducted a planned economic analysis of a multicenter, open-label, randomized phase IV trial that included patients in Nepal, Singapore, and Thailand.
  4. Current guidelines recommend 7 to 8 days of antibiotic therapy for ventilator-associated pneumonia.
  5. The shorter individualized strategy was considered cost-saving in Singapore and cost-effective in Nepal and Thailand. 

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.